Barclays Keeps Their Buy Rating on Genmab A/S (0MGB)
In a report released today, Emily Field from Barclays maintained a Buy rating on Genmab A/S (0MGB – Research Report), with a price target of ...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Leerink raises Genmab stock rating to outperform, PT steady at $27
Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...
Genmab (GMAB) Gets a Hold from Morgan Stanley
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Genmab stock rating raised, price target cut by BNP Paribas Exane
Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...
Q3 Earnings Forecast for Genmab A/S Issued By William Blair
Equities researchers at William Blair issued their Q3 2025 earnings per share estimates for Genmab A/S in a research note issued on Thursday, February 13th. William Blair analyst M. Phipps forecasts ...
Leerink Partnrs Estimates Genmab A/S Q3 Earnings
Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
Seeking Alpha4d
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript
which is equivalent to around $370 million at our current stock price. This underscores our confidence in Genmab's future and our commitment to delivering value to our shareholders, both in the ...